Evidence map›Paper›PMID 33071710›Full record

ArticleAdvanced functional materials2020

Poly(cyclodextrin)-Polydrug Nanocomplexes as Synthetic Oncolytic Virus for Locoregional Melanoma Chemoimmunotherapy.

Jihoon Kim, Lauren F Sestito, Sooseok Im, Won Jong Kim, Susan N Thomas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Application of Cyclodextrin for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Elicitation of stem-like CD8Journal for immunotherapy of cancer · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jihoon KimParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, Georgia 30332; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, Georgia 30332, USA.
Lauren F SestitoWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, Georgia 30332, USA and Emory University, 201 Dowman Drive, Atlanta, Georgia 30322, USA.
Sooseok ImSchool of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
Won Jong KimSchool of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea; Department of Chemistry, POSTECH, Pohang 37673, Republic of Korea.
Susan N ThomasParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, Georgia 30332; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, Georgia 30332, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, Georgia 30332, USA and Emory University, 201 Dowman Drive, Atlanta, Georgia 30322, USA; Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road NE, Atlanta, Georgia 30322, USA.
Georgia Institute of Technology · USPohang University of Science and Technology · KR

Funding

Graduate Training for Rationally Designed, Integrative Biomaterials - GT BioMATT32EB006343 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI TEMENOFF, JOHNNA S · 2008 to 2018
$2.2M
Melanoma immunotherapy targeting sentinel lymph nodesR01CA207619 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI THOMAS, SUSAN NAPIER · 2016 to 2020
$2.0M
IVIS Spectrum in vivo Imaging SystemS10OD016264 · OD · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2015 to 2015
$595k
Role of HIV-1 Tat in the activation of HERV-K and development of HIV-1-lymphomaF31CA150523 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GONZALEZ-HERNANDEZ, MARTA JEANNETTE · 2010 to 2011
$65k
NCI NIH HHS F31 CA150523NCI NIH HHS R01 CA207619NIBIB NIH HHS T32 EB006343NIH HHS S10 OD016264
6 · The paper itself

Abstract

Despite the approval of oncolytic virus therapy for advanced melanoma, its intrinsic limitations that include the risk of persistent viral infection and cost-intensive manufacturing motivate the development of analogous approaches that are free from the disadvantages of virus-based therapies. Herein, we report a nanoassembly comprised of multivalent host-guest interactions between polymerized paclitaxel (pPTX) and nitric oxide incorporated polymerized β-cyclodextrin (pCD-pSNO) that through its bioactive components and when used locoregionally recapitulates the therapeutic effects of oncolytic virus. The resultant pPTX/pCD-pSNO exhibits significantly enhanced cytotoxicity, immunogenic cell death, dendritic cell activation and T cell expansion

Indexed as

CancerChemotherapyImmunotherapyNitric oxidePaclitaxel

Identifiers

PMID33071710
PMCPMC7566879
OpenAlexW3006969333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.